Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 2, 2005, Pages 185-188

  Wiseman, Gregory A ^a   Witzig, Thomas E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Durable responses; Non Hodgkin's lymphoma; Time to progression; Yttrium 90 ibritumomab tiuxetan

Indexed keywords

IBRITUMOMAB TIUXETAN; CD20 ANTIGEN; MONOCLONAL ANTIBODY; YTTRIUM;

ADULT; AGED; B CELL LYMPHOMA; BONE MARROW; CANCER GROWTH; CANCER RELAPSE; CONFERENCE PAPER; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME; ARTICLE; BIOSYNTHESIS; DISEASE COURSE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 18844435974     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.185     Document Type: Conference Paper

References (13)

1. Chakrabarti MC, Le N, Paik CH, et al. Prevention of radiolysis of monoclonal antibody during labeling. J Nucl Med 1996;37:1384.
2. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B-cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711.
3. Valentine MA, Meier KE, Rossie S, et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989;264:11282.
4. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5:3281S.
5. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkins' lymphoma. Int J Oncol 1999;15:1017.
6. 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med Biol 1991;18:469.
7. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal-labeled monoclonal antibodies. Int J Rad Appl Instrum B 1991;18:389.
8. Wagner HNJ, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkins' lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267.
9. Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkins' lymphoma. Cancer 2002;94:1349.
10. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkins' lymphoma. J Clin Oncol 1999;17:3793.
11. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkins' lymphoma. J Clin Oncol 2002;20:2453.
12. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkins' lymphoma. J Clin Oncol 2002;20:3262.
13. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin's lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 2002;99:4336.